A summary of base estimate probabilities for various clinical events associated with the treatment options was as follows ( Plausible Range' in parentheses):
Sequelae of persistent cervical chlamydia:
Symptomatic pelvic inflammatory disease 0.15 (0.08 -0.20);
Outpatient treatment 0.86 (0.80 - 0.92);
Inpatient treatment 0.14 (0.08 -0.20);
Sequelae of symptomatic pelvic inflammatory disease:
Infertility 0.17 (0.08 -0.20);
Ectopic pregnancy (0.08 (0.05 - 0.10);
Chronic pelvic pain 0.12 (0.08-0.16);
Newly infected partners per woman with persistent chlamydia 1.00 (0.75 - 1.25);
Sequelae for infected male partners:
Symptomatic urethritis 0.50 (0.35-0.65);
Epididymitis 0.02 (0.01-0.04);
Outpatient treatment 0.90 (0.85-0.95);
Inpatient treatment 0.10 (0.05-0.15).
Sequelae for children born to infected mothers:
Neonatal conjunctivitis 0.20 (0.15-0.25);
Neonatal Pneumonia 0.10 (003-0.16);
Outpatient Treatment 0.80 (0.70-0.90);
Inpatient Treatment 0.20 (0.110 -0.30).
Antibiotic effectiveness:
DC 0.86 (0.80-0.90);
AZ 0.96 (0.94-0.98).
Adverse reactions to oral DC:
Minor reactions 0.16 (0.10-0.20);
Major reactions 0.001 (0.0001-0.001).
Adverse reactions to oral AZ:
Minor reactions 0.13 (0.10-0.20);
Major reactions 0.0001 (0.0001-0.001).